Key statistics
On Friday, Uniqure NV (UQ1:FRA) closed at 4.90, 48.52% above the 52 week low of 3.30 set on Jul 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.90 |
---|---|
High | 4.90 |
Low | 4.90 |
Bid | 4.63 |
Offer | 4.94 |
Previous close | 5.05 |
Average volume | 298.10 |
---|---|
Shares outstanding | 48.70m |
Free float | 46.59m |
P/E (TTM) | -- |
Market cap | 276.12m USD |
EPS (TTM) | -5.92 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 07:21 BST.
More ▼
- uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
- uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
- uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
- uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
- uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
- uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
- uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
- uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼